GT BIOPHARMA, INC. Other Noncash Expense
GT BIOPHARMA, INC. (GTBP) reported Other Noncash Expense of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashExpense · last filed 2021-12-29
- GT BIOPHARMA, INC. other noncash expense for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. other noncash expense for the quarter ending 2020-09-30 was $15.00K.
| Period end | Other Noncash Expense 3 month | Other Noncash Expense 6 month | Other Noncash Expense 9 month |
|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $0.00 10-Q/A · filed 2021-12-29 | ||
| 2020-09-30 | $15.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-11-10 | $3.97M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.96M 10-Q/A · filed 2021-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |